Pulse Biosciences (PLSE)

The company also refers to its platform as nanosecond pulsed field ablation, or nsPFA. Pulsed field ablation has attracted interest across medicine because it may offer a more selective way to treat unwanted cells or tissue. Pulse Biosciences is focused on translating this energy modality into medical applications where precision, safety, and control are central to adoption. Its programs sit at the intersection of device engineering, electrophysics, and clinical medicine.

As a development-oriented healthcare company, Pulse Biosciences’ value is tied to the strength of its intellectual property, the performance of its systems in clinical settings, and its ability to obtain regulatory clearances or approvals. Commercial success also depends on physician adoption, reimbursement, manufacturing execution, and evidence that its technology can improve outcomes or workflow compared with existing procedures.

For investors, the company represents exposure to a specialized segment of medtech rather than a conventional pharmaceutical model. Its progress is typically assessed through product development milestones, regulatory updates, clinical results, and the size of the medical markets in which its nsPFA technology can be applied.